The Immune Response

to Cancer Diagnostics

 

 

In the media :

Wednesday 19 April 2017 - OncLive:   Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC    |     Friday 14 April 2017 - Cancer Network:   Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer    |     Wednesday 12 April 2017 - Publicnow:   Targeting blood vessels to improve cancer immunotherapy    |     Monday 03 April 2017 - Health Medicine Network:   Patients’ defence complement might change efficacy of cancer immunotherapy    |     Saturday 01 April 2017 - Money:   HalioDx: New data on Halioseek(TM) PD-L1/CD8 presented at AACR 2017    |     Thursday 30 March 2017 - Pharmacy Choice:   3/30/17 - HalioDx performed development work for ipsogen JAK2 510(k) clearance by QIAGEN    |     Thursday 30 March 2017 - L'Espace Datapresse:   HALIODX PARTAGE LE SUCCÈS DE QIAGEN QUI VIENT D'OBTENIR L'AGRÉMENT 510(K) DE LA FDA POUR LE TEST IPSOGEN® JAK2    |     Tuesday 21 March 2017 - Journal for ImmunoTherapy of Cancer:   Systematic evaluation of immune regulation and modulation    |     Tuesday 21 March 2017 - Journal for ImmunoTherapy of Cancer:   Immunotherapy biomarkers 2016: overcoming the barriers    |     Sunday 19 March 2017 - Metronews.fr:   Recherche : l'immunothérapie, traitement prometteur contre le cancer    |